{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444574102
| IUPAC_name = 4-({(4-carboxybutyl)[2-(2-<nowiki/>{[4-(2-phenylethyl)<br />phenyl]methoxy}phenyl)ethyl]amino}methyl)<br />benzoic acid
| image = Cinaciguat_structure.svg

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = [[intravenous]] (?)

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| IUPHAR_ligand = 5168
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 329773-35-5
| CAS_supplemental = 
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 9808022
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 59K0Y58UAD
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 7983781
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = WPYWMXNXEZFMAK-UHFFFAOYSA-N

<!--Chemical data-->
| chemical_formula = 
| C=36 | H=39 | N=1 | O=5 
| molecular_weight = 565.697 g/mol
| smiles = c4ccccc4CCc3ccc(cc3)COc1ccccc1CCN(CCCCC(O)=O)Cc2ccc(C(=O)O)cc2
}}

'''Cinaciguat''' ('''BAY 58-2667''') is an experimental drug for the treatment of [[acute decompensated heart failure]].

==Mechanism of action==
Cinaciguat activates the [[soluble guanylate cyclase]] (sGC) which is a receptor for [[nitric oxide]]. This increases biosynthesis of [[cyclic GMP]], resulting in [[vasodilation]].<ref>Schubert-Zsilavecz, M, Wurglics, M, ''Neue Arzneimittel 2009''</ref>

==See also==
*[[Riociguat]], another drug stimulating sGC, but with a different mechanism
* [[PDE5 inhibitor]]s act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

== References ==
{{Reflist}}


{{Nitric oxide signaling}}

[[Category:Vasodilators]]
[[Category:Benzoic acids]]
[[Category:Phenol ethers]]


{{cardiovascular-drug-stub}}